SPRED2 Negatively Regulates CD8+ T Cell‐Mediated Antitumor Immunity in Breast Cancer
Miao Tian, Teizo Yoshimura, Kun Zhao, Chunning Li, Tong Gao, Ziyi Wang, Masayoshi Fujisawa, Toshiaki Ohara, Akihiro Matsukawa · 2026
Read SPRED2 Negatively Regulates CD8+ T Cell‐Mediated Antitumor Immunity in Breast Cancer by Miao Tian, Teizo Yoshimura, Kun Zhao, Chunning Li, Tong Gao, Ziyi Wang, Masayoshi Fujisawa, Toshiaki Ohara, Akihiro Matsukawa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13616240.txt.
Description
Miao Tian leads a team showing that a brake protein called SPRED2 holds back the immune attack on breast cancer, working in two mouse models of the disease. SPRED2 normally restrains a growth signal pathway that killer T cells also need. Mice lacking the protein grew smaller tumours, carried fewer lung metastases in one model, and packed more active T cells into their tumours.
T cells without SPRED2 made more attack chemicals, multiplied and survived better, and killed cancer cells more strongly in dishes. Moving those cells into normal tumour-bearing mice also cut lung spread. A drug that blocks the pathway cancelled the boost, confirming the route. The results mark SPRED2 as a possible drug target: releasing this one brake might sharpen the body's own cancer defence.
Catalog record
| CREATOR | Miao Tian, Teizo Yoshimura, Kun Zhao, Chunning Li, Tong Gao, Ziyi Wang, Masayoshi Fujisawa, Toshiaki Ohara, Akihiro Matsukawa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |